On May 8, 2017, Alimera Sciences, Inc. (Alimera) issued a press
release regarding its results of operations and financial
condition for the first quarter ended March 31, 2017. Alimera
will be hosting a conference call, as well as a live webcast on
the Investor Relations section of its corporate website at
www.alimerasciences.com, on May 9, 2017 at 8:00 A.M. ET to
discuss its first quarter ended March 31, 2017 financial results
and to provide regulatory and commercial updates. The full text
of the press release, which includes information regarding
Alimeras use of non-GAAP financial measures, is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.

Various statements to be made during the conference call and
webcast, including the slide deck presentation discussed in Item
7.01 of this Current Report on Form 8-K, are forward-looking
statements, within the meaning of the Private Securities
Litigation Reform Act of 1995, regarding, among other things, the
growth potential of ILUVIEN, the adoption of reimbursement coding
in the Middle East, Alimeras need for additional financing, and
the potential for Alimera to expand geographically, extend the
ILUVIEN label and become cash flow positive. Words such as
anticipate, believe, estimate, expect, intend, may, plan,
contemplate, predict, project, target, likely, potential,
continue, ongoing, will, would, should, could, or the negative of
these terms and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such forward-looking
statements are based on current expectations and involve inherent
risks and uncertainties, including factors that could delay,
divert or change any of them, and could cause actual results to
differ materially from those projected in its forward-looking
statements. Meaningful factors which could cause actual results
to differ include, but are not limited to, market acceptance and
physician awareness of ILUVIEN in the U.S. and Europe, the
regulatory environment in the Middle East and elsewhere, the
outcome of future clinical trials, Alimeras ability to contain
its operating expenses, as well as other factors discussed in the
Risk Factors and Managements Discussion and Analysis of Financial
Condition and Results of Operations sections of Alimeras Annual
Report on Form 10-K for the year ended December 31, 2016, which
is on file with the Securities and Exchange Commission (SEC) and
available free of charge on the SECs website at www.sec.gov.
Additional factors may also be set forth in those sections of
Alimeras Quarterly Report on Form 10-Q for the three months ended
March 31, 2017, to be filed with the SEC in the second quarter of
2017. In addition to the risks described above and in Alimeras
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8-K and other filings with the SEC, other
unknown or unpredictable factors also could affect Alimeras
results. There can be no assurance that the actual results or
developments anticipated by Alimera will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Alimera. Therefore, no assurance
can be given that the outcomes stated in such forward-looking
statements and estimates will be achieved.

All forward-looking statements made during the conference call
and webcast are expressly qualified by the cautionary statements
contained or referred to herein. Alimera cautions investors not
to rely too heavily on the forward-looking statements Alimera
makes or that are made on its behalf. These forward-looking
statements speak only as of the date on which they are made
(unless another date is indicated). Alimera undertakes no
obligation, and specifically declines any obligation, to publicly
update or revise any such forward-looking statements, whether as
a result of new information, future events or otherwise.

The information in Item 2.02 of this Current Report on Form 8-K
and the press release furnished as Exhibit 99.1 hereto shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended (the “Securities Act”), or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

Item 7.01. Regulation FD.

Alimera is furnishing under this Item 7.01 a copy of a slide deck
presentation which will be available May 9, 2017 on Alimeras
earnings webcast for the first quarter ended March 31, 2017. The
presentation is incorporated by reference herein. Certain
financial information relating to completed fiscal periods that
will be part of the earnings webcast is included in the
presentation that will accompany the earnings webcast, a copy of
which is attached hereto as Exhibit 99.2. The earnings webcast
will include certain non-GAAP financial measures. Reconciliations
of these non-GAAP financial measures to the comparable measures
calculated and presented in accordance with GAAP are included in
Alimeras press release issued May 8, 2017 and attached hereto as
Exhibit 99.1.

The information in this Current Report on Form 8-K under Item
7.01, including Exhibit 99.2 attached hereto and incorporated
herein, is being furnished and not filed with the SEC for
purposes of Section 18 of the Exchange Act, or otherwise subject
to the liabilities under such section. Furthermore, such
information shall not be deemed incorporated by reference in any
filing under the Securities Act, unless specifically identified
as being incorporated therein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits